Showing results (4031-4040 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|April 5, 2022
Pembrolizumab and Trastuzumab in High Tumor Mutational Burden and POLE-Mutated HER2-Positive Refractory Breast CancerLi Zhang, Yimeng Chen, Yao Lv, et al.
The Oncologist|April 5, 2022
Joint-Predominant Rheumatic Complications of Immune Checkpoint Inhibitor Therapy in Patients with Thymic Epithelial TumorsCristina Mullenix, Madison Ballman, Haobin Chen, et al.
The Oncologist|April 5, 2022
Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)Jin Matsuyama, Tetsuji Terazawa, Masahiro Goto, et al.
The Oncologist|April 6, 2022
"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome ManagementSalma Shickh, Leslie E Oldfield, Marc Clausen, et al.
The Oncologist|April 24, 2022
Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple MyelomaAndrzej J Jakubowiak, Shaji Kumar, Rohan Medhekar, et al.
The Oncologist|May 23, 2023
Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors TreatmentChenchen Ji, Feng Li, Yang Yuan, et al.
The Oncologist|April 13, 2023
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II TrialKeiko Tanimura, Junji Uchino, Hideharu Kimura, et al.
The Oncologist|April 13, 2023
Diffuse Large B-Cell Lymphoma Treated With R-CHOP in a Resource-Limited Setting in South Africa: A Real-World StudyZola Musimar, Mtonga Mpetani, Jeremy S Abramson, et al.
The Oncologist|March 30, 2021
Risk of COVID-19 in Patients with Cancer Receiving Immune Checkpoint InhibitorsNikolai Klebanov, Vartan Pahalyants, William S Murphy, et al.
The Oncologist|May 12, 2023
Treatment of Cancer-Associated Thrombosis: Recent Advances, Unmet Needs, and Future DirectionTzu-Fei Wang, Alok A Khorana, Giancarlo Agnelli, et al.
Pageof 571